Demonstrated Efficacy of ARZERRA Plus Bendamustine

Previously Untreated Patients With CLL Achieved ORR of 95% and CR of 43% When Treated With ARZERRA Plus Bendamustine1,a

  • More than half of the patients (56%) with CR were MRD-negative following the completion of study treatment1
aUntreated CLL patients inappropriate for fludarabine therapy, n=44.
CLL, chronic lymphocytic leukemia; CR, complete response; MRD, minimal residual disease; ORR, overall response rate.

Learn more about the study design and patient characteristics of this study.

Reference: 1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2016.